AZ, Daiichi ink co-marketing deal on Nexium

AstraZeneca (AZN.L) and Daiichi Sankyo (4568.T) said they have agreed to co-promote and supply the heartburn treatment Nexium in Japan in a deal that includes a $100 million up-front payment to AstraZeneca. Report

Suggested Articles

Eli Lilly
Pharma

Lilly scores FDA nod for new migraine drug Reyvow

While Lilly's 2018 launch Emgality is approved to prevent migraines, Reyvow is intended to treat them as they occur.

by Eric Sagonowsky
Drug prices
Pharma

ICER says AbbVie's RA newcomer Rinvoq may be cost-effective

ICER's new draft review of RA drugs takes a different approach, reflecting how physicians treat the disease and the time horizon that's considered.

by Arlene Weintraub
J&J
Pharma

J&J, besieged by lawsuits, could be a steal for investors

Johnson & Johnson is facing multibillion-dollar liabilities in thousands of talc and opioid cases. But that's not such a bad thing, one analyst said.

by Kyle Blankenship